March 7, 2012
Since the launch of Uniferon® 100 and Uniferon® 200 on the US
Market in April last year, Uniferon has grown to become the no. 1
injectable dextran iron supplementation on this important
market.
This positive development is not least due to the diligent work
of associated partner Ivesco, but must also be seen in the light of
the sheer ability to provide a consistently high quality product to
swine producers all over the US.
The AASV - staying at the forefront
The American Association of Swine Veterinarians (AASV) hosts
one of the most important conventions within the international pig
farming community. From the 10th-13th of March, we will therefore
be present at the convention in Denver, Colorado.
The topic of this year's convention is: "Integrating Science,
Welfare, and Economics in Practice".
AASV's own Tara Donovan writes in the preface to this year's
program: "With the turbulent economic situation in our country,
improving business viability is the key to success. In pork
production, business viability is directly influenced by the health
and performance of the pig."
At Pharmacosmos, we are present at the AASV to ensure that
Uniferon continues to play an important role in the health and
performance of US pigs.
The AASV is an excellent opportunity to meet and network with
some of the most important industry members, and it is also a
chance to stay at the very forefront of developments within the
areas of pigs' health and growth. We will actively participate by
presenting a poster and address issues of importance directly to
the pig farming community.
About Uniferon
Uniferon is a modern improved iron hydrogenated dextran based on
a natural formula, which is approved for global use:
Uniferon is manufactured without the use of any organic solvents
or cyanide, thus, avoiding trace residues of these impurities.
Pharmacosmos manufactures iron dextran of high quality and unique
purity for customers worldwide. Uniferon is the only injectable
iron brand for piglets approved in the EU, the US and Asia.
About Pharmacosmos
Headquartered in Denmark, Pharmacosmos is a family-owned,
international healthcare company with more than 50 years of
innovation and leadership in iron- and carbohydrate-based
treatments and solutions for human and animal use.
A research-based company, its ongoing R&D programme focuses
on improving the lives of patients with iron deficiency with or
without anaemia. More than 1 billion people live with iron
deficiency anaemia and it is the leading cause of death for an
estimated 180,000 people every year. This makes it one of the
largest global health challenges of our time.
Pharmacosmos has subsidiaries in the Nordics, the UK and the US
and its products are marketed in more than 80 countries across the
world. Its manufacturing facilities are approved, among others, by
the Danish Medicines Agency and the US FDA.